CN118086272A - High-efficiency nitrilase immobilization method and its application - Google Patents
High-efficiency nitrilase immobilization method and its application Download PDFInfo
- Publication number
- CN118086272A CN118086272A CN202410214810.0A CN202410214810A CN118086272A CN 118086272 A CN118086272 A CN 118086272A CN 202410214810 A CN202410214810 A CN 202410214810A CN 118086272 A CN118086272 A CN 118086272A
- Authority
- CN
- China
- Prior art keywords
- nitrilase
- immobilized
- enzyme
- acn
- phosphate buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010033272 Nitrilase Proteins 0.000 title claims abstract description 104
- 238000000034 method Methods 0.000 title claims abstract description 89
- 102000004190 Enzymes Human genes 0.000 claims abstract description 130
- 108090000790 Enzymes Proteins 0.000 claims abstract description 130
- 239000011347 resin Substances 0.000 claims abstract description 71
- 229920005989 resin Polymers 0.000 claims abstract description 71
- 238000001179 sorption measurement Methods 0.000 claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 47
- 238000006243 chemical reaction Methods 0.000 claims abstract description 45
- 239000000758 substrate Substances 0.000 claims abstract description 32
- 241000894006 Bacteria Species 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 239000002773 nucleotide Substances 0.000 claims abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 51
- 108010093096 Immobilized Enzymes Proteins 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 102000004169 proteins and genes Human genes 0.000 claims description 37
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 33
- 239000000047 product Substances 0.000 claims description 20
- 239000008367 deionised water Substances 0.000 claims description 19
- 229910021641 deionized water Inorganic materials 0.000 claims description 19
- YGFXLCAKCKPSQQ-UHFFFAOYSA-N 2-(1-cyanocyclohexyl)acetic acid Chemical compound OC(=O)CC1(C#N)CCCCC1 YGFXLCAKCKPSQQ-UHFFFAOYSA-N 0.000 claims description 16
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 15
- 238000011068 loading method Methods 0.000 claims description 14
- CYMZDPHCBAWUHZ-UHFFFAOYSA-N 1-(cyanomethyl)cyclohexane-1-carbonitrile Chemical compound N#CCC1(C#N)CCCCC1 CYMZDPHCBAWUHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000000502 dialysis Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 239000012065 filter cake Substances 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 7
- 229930027917 kanamycin Natural products 0.000 claims description 7
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 7
- 229960000318 kanamycin Drugs 0.000 claims description 7
- 229930182823 kanamycin A Natural products 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000012880 LB liquid culture medium Substances 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 230000003100 immobilizing effect Effects 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 239000002054 inoculum Substances 0.000 claims description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 238000000825 ultraviolet detection Methods 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 239000012429 reaction media Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 70
- 238000011084 recovery Methods 0.000 abstract description 10
- 238000012258 culturing Methods 0.000 abstract description 2
- 229940088598 enzyme Drugs 0.000 description 114
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 50
- 229960002870 gabapentin Drugs 0.000 description 24
- 238000004132 cross linking Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 12
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 12
- 238000003860 storage Methods 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000001961 anticonvulsive agent Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- 238000003795 desorption Methods 0.000 description 4
- 238000001952 enzyme assay Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229960003965 antiepileptics Drugs 0.000 description 3
- 239000011942 biocatalyst Substances 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079919 digestives enzyme preparation Drugs 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000007306 functionalization reaction Methods 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 239000002351 wastewater Substances 0.000 description 3
- 241000726118 Acidovorax facilis Species 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 108010029541 Laccase Proteins 0.000 description 2
- 108010059881 Lactase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000007098 aminolysis reaction Methods 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229940116108 lactase Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- -1 1-cyanocyclohexylacetyl Chemical group 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 1
- 101001121408 Homo sapiens L-amino-acid oxidase Proteins 0.000 description 1
- 102100026388 L-amino-acid oxidase Human genes 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- 108010007843 NADH oxidase Proteins 0.000 description 1
- 108010024026 Nitrile hydratase Proteins 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- 239000003225 biodiesel Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- 235000012255 calcium oxide Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229940000041 nervous system drug Drugs 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000010641 nitrile hydrolysis reaction Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- CLURAKRVQIPBCC-UHFFFAOYSA-M sodium;perbromate Chemical compound [Na+].[O-]Br(=O)(=O)=O CLURAKRVQIPBCC-UHFFFAOYSA-M 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
- C12N11/087—Acrylic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/002—Nitriles (-CN)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/05—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in nitriles (3.5.5)
- C12Y305/05001—Nitrilase (3.5.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
Description
(一)技术领域(I) Technical field
本发明属于生物工程技术领域,具体涉及一种高效腈水解酶固定化方法及在制备1-氰基环己基乙酸中的应用。The invention belongs to the technical field of bioengineering, and in particular relates to a method for immobilizing a high-efficiency nitrilase and an application thereof in preparing 1-cyanocyclohexyl acetic acid.
(二)背景技术(II) Background technology
游离酶难以从反应中分离出来,通常在一次性使用后丢弃,经济成本较高。提高酶的生产效率并延长其使用周期是生物工程领域的重大需求。酶固定化技术可以将游离酶转化为固态,固定化酶相比游离酶更稳定、更耐环境变化,酶易于与反应体系分离,还具有较高的安全性和可持续性。更重要的是,固定化酶具有较强的重复使用性,利于连续操作和反应的快速终止,为生物反应器的设计提供了更多可能性。酶的固定化技术一直广泛应用于医药工业领域,如作为催化剂催化药物和中间体合成,固定化酶还可用于诊断或治疗疾病,固定化细胞也可用于人工材料的涂层,以提高生物相容性等。固定化酶和细胞在食品工业、营养学、生物能源、纺织工业中也有较多应用。Free enzymes are difficult to separate from the reaction and are usually discarded after a single use, which has a high economic cost. Improving the production efficiency of enzymes and extending their service life is a major demand in the field of bioengineering. Enzyme immobilization technology can convert free enzymes into solid state. Immobilized enzymes are more stable and more resistant to environmental changes than free enzymes. Enzymes are easy to separate from the reaction system and have high safety and sustainability. More importantly, immobilized enzymes have strong reusability, which is conducive to continuous operation and rapid termination of reactions, providing more possibilities for the design of bioreactors. Enzyme immobilization technology has been widely used in the pharmaceutical industry, such as as a catalyst to catalyze the synthesis of drugs and intermediates. Immobilized enzymes can also be used to diagnose or treat diseases. Immobilized cells can also be used for coatings of artificial materials to improve biocompatibility. Immobilized enzymes and cells are also widely used in the food industry, nutrition, bioenergy, and textile industries.
加巴喷丁(Gabapentin)化学名1-(氨甲基)-环己基乙酸,是由Warner-Lambert公司研发的抗癫痫药物,于1993年在英国上市。加巴喷丁对顽固性癫痫(Intractableepilepsy,IE)尤其对部分性癫痫发作(伴有或不伴有全身性发作)有选择性作用,具有治疗指数高的特点,耐受性好,毒性小,无致畸、致突变作用,副作用短暂且轻微,无严重或慢性不良反应,是一种新型抗癫痫药。近些年,加巴喷丁治疗的适应症不断扩大,也用于治疗神经性疼痛综合征,包括三叉神经痛、围手术期神经疼痛、偏头痛、带状疱疹后神经痛等等。与其他类似药物相比,加巴喷丁疗效更好,毒副作用较小,还有耐受性好等优点,在临床应用中更受欢迎。相关资料显示,加巴喷丁在国内的销售市场有较快增长。加巴喷丁已经被收录进中国药典2020版,属于1类神经系统药物,2类抗癫痫药,且进入了《国家医保药品目录》,被列为乙类药物。近几年,在公立医疗机构终端抗癫痫药金额统计中,加巴喷丁的用药金额在不断上升。2019年,中国公立医疗机构终端化学药抗癫痫药通用名排名榜中,加巴喷丁胶囊排名第七,占市场份额约4.14%,但与国际市场差距还较大。据预测,由于中国和全球癫痫、神经痛患者人数众多,加之加巴喷丁临床效果优秀,其市场仍有较大发展潜力,加巴喷丁药品和原料药全球需求仍将逐年上升。Gabapentin, chemical name 1-(aminomethyl)-cyclohexylacetic acid, is an anti-epileptic drug developed by Warner-Lambert and launched in the UK in 1993. Gabapentin has a selective effect on intractable epilepsy (IE), especially partial epileptic seizures (with or without generalized seizures). It has the characteristics of high therapeutic index, good tolerance, low toxicity, no teratogenic or mutagenic effects, short-term and mild side effects, and no serious or chronic adverse reactions. It is a new type of anti-epileptic drug. In recent years, the indications for gabapentin treatment have been continuously expanded, and it is also used to treat neuropathic pain syndromes, including trigeminal neuralgia, perioperative neuralgia, migraine, postherpetic neuralgia, etc. Compared with other similar drugs, gabapentin has better efficacy, fewer toxic side effects, and good tolerance, and is more popular in clinical applications. Relevant data show that the sales market of gabapentin in China has grown rapidly. Gabapentin has been included in the 2020 edition of the Chinese Pharmacopoeia as a Class 1 nervous system drug and a Class 2 anti-epileptic drug. It has also been included in the National Medical Insurance Drug Catalogue and is listed as a Class B drug. In recent years, the amount of gabapentin used in the statistics of terminal anti-epileptic drugs in public medical institutions has continued to rise. In 2019, gabapentin capsules ranked seventh in the generic name ranking of terminal chemical anti-epileptic drugs in China's public medical institutions, accounting for about 4.14% of the market share, but there is still a large gap with the international market. It is predicted that due to the large number of epilepsy and neuralgia patients in China and the world, and the excellent clinical effect of gabapentin, its market still has great development potential, and the global demand for gabapentin drugs and APIs will continue to increase year by year.
加巴喷丁有多种合成途径,大致可分为化学法和化学-酶法两大类。大多数受关注的化学途径以环己酮为原料,通过环化、水解、缩合、氨解等步骤化学合成加巴喷丁:Caiming等人从环己酮出发,主要经过Wittig反应、螺环构筑、重排反应、开环反应以及离子交换等获得产物加巴喷丁。Jin-Pei Huang等人利用环己酮在乙醇和一水合氨的催化下发生环合反应,产物在80%硫酸条件下酸解生成双羧酸,与乙酸酐进行缩合反应,加入羟基胺盐酸盐进行氨解,最后与高溴酸钠在氢氧化钠碱性条件下反应生成产物加巴喷丁。此路线的产物收率较高,但需要大量浓硫酸,产生大量黑色酸性废水,对环境污染较大;处理此污水还需要大量生石灰中和,此过程会严重腐蚀设备并增加废渣,而且水解后的黑色产物还要进行脱色处理,又增加了工序。There are many synthetic routes for gabapentin, which can be roughly divided into two categories: chemical method and chemical-enzymatic method. Most of the chemical routes that have attracted attention use cyclohexanone as the raw material to chemically synthesize gabapentin through steps such as cyclization, hydrolysis, condensation, and aminolysis: Caiming et al. started from cyclohexanone and obtained the product gabapentin mainly through Wittig reaction, spiro ring construction, rearrangement reaction, ring opening reaction, and ion exchange. Jin-Pei Huang et al. used cyclohexanone to undergo a cyclization reaction under the catalysis of ethanol and monohydrate ammonia. The product was acidified under 80% sulfuric acid to generate dicarboxylic acid, which was condensed with acetic anhydride, and hydroxylamine hydrochloride was added for aminolysis. Finally, it was reacted with sodium perbromate under alkaline conditions of sodium hydroxide to generate the product gabapentin. The product yield of this route is high, but a large amount of concentrated sulfuric acid is required, which produces a large amount of black acidic wastewater, which is highly polluting to the environment; the treatment of this wastewater also requires a large amount of quicklime to neutralize it, which will seriously corrode the equipment and increase the waste residue. In addition, the black product after hydrolysis must be decolorized, which adds another process.
多数加巴喷丁的化学合成路线都存在较多缺点。而使用腈水解酶区域选择性水解双腈底物,生成羧基腈中间体,再还原氰基生成加巴喷丁的化学-酶法合成路线,具有操作简单、原料价廉易得、反应条件温和、反应过程较易控制、催化选择性极高、反应收率高、危险性低而且绿色环保、等巨大优势。其合成路径已经过本实验室前期开发验证,具有很好的工业应用潜力。化学-酶法合成路线如下(图1);底物1-氰基环己基乙腈在腈水解酶催化下,一步合生成1-氰基环己基乙酸,再加氢生成产物加巴喷丁及其内酰胺,或者使用另一种相似的路线即底物1-氰基环己基乙腈在腈水合酶催化下生成1-氰基环己基乙酰,再通过酰胺酶水解生成1-氰基环己烷乙酸,后续生成加巴喷丁的步骤同上。Most chemical synthesis routes of gabapentin have many disadvantages. The chemical-enzymatic synthesis route of using nitrilase to regioselectively hydrolyze the dinitrile substrate to generate a carboxynitrile intermediate, and then reducing the cyano group to generate gabapentin has great advantages such as simple operation, cheap and readily available raw materials, mild reaction conditions, easy control of the reaction process, extremely high catalytic selectivity, high reaction yield, low risk and green environmental protection. Its synthesis route has been verified by the preliminary development of this laboratory and has great potential for industrial application. The chemical-enzymatic synthesis route is as follows (Figure 1); the substrate 1-cyanocyclohexylacetonitrile is catalyzed by nitrilase to generate 1-cyanocyclohexylacetic acid in one step, and then hydrogenated to generate the product gabapentin and its lactam, or another similar route is used, that is, the substrate 1-cyanocyclohexylacetonitrile is catalyzed by nitrile hydratase to generate 1-cyanocyclohexylacetyl, and then hydrolyzed by amidase to generate 1-cyanocyclohexaneacetic acid, and the subsequent steps of generating gabapentin are the same as above.
然而加巴喷丁化学-酶法的工业应用受到生物催化剂操作、储存稳定性差以及难以回收利用等阻碍。游离细胞或粗酶、游离酶作为催化剂的稳定性较差,易变性失活,细胞或酶只能一次性使用,增加了酶制剂成本与废水、废渣排放;酶与底物和产物的混合加大了产物的分离纯化的难度,影响产品收率,增加生产成本。固定化酶或细胞是这些问题的解决方法之一。通常情况下,固定化可以提高酶的耐受性,保护酶不受恶劣条件的影响,或在反应过程中使酶蛋白保持稳定,并实现酶的循环利用,降低酶制剂成本,提高产品产率。However, the industrial application of gabapentin chemical-enzymatic method is hindered by poor operation and storage stability of biocatalysts and difficulty in recycling. Free cells or crude enzymes, free enzymes have poor stability as catalysts, are easily denatured and inactivated, and cells or enzymes can only be used once, which increases the cost of enzyme preparations and the discharge of wastewater and waste residues; the mixing of enzymes with substrates and products increases the difficulty of separation and purification of products, affects product yields, and increases production costs. Immobilized enzymes or cells are one of the solutions to these problems. Generally, immobilization can improve the tolerance of enzymes, protect enzymes from adverse conditions, or keep enzyme proteins stable during the reaction process, and realize the recycling of enzymes, reduce the cost of enzyme preparations, and improve product yields.
固定化酶技术在生物催化中应用广泛。Wu等人使用硅藻土和大孔树脂HPD-417作为吸附载体,与纤维素衍生物膜涂层结合固定化漆酶。制备得的硅藻土和HPD-417固定化漆酶的酶活回收率可达到99.33%和94.15%,热稳定性和pH耐受性有较大提升,在环境治理中有很好的潜力。Nuraliyah等人使用大孔阴离子树脂MP-64和经过壳聚糖处理的大孔非离子树脂XAD-7HP吸附脂肪酶,再用戊二醛交联,制备得到的MP-64树脂固定化酶的酶活回收率和比酶活达到了83.79%和29.41U/g,固定化酶四次循环使用后,生物柴油合成率为初始产量的70.61%。Meng-Qiu Xu等人把甘油脱氢酶和NADH氧化酶共固定化为交联酶聚集体,构建NAD+再生体系,该交联酶聚集体的比酶活为950U/g,对溶液pH和温度的稳定性优于游离酶,经过10批次重复使用后剩余活性仍有63.3%,其催化甘油合成1,3-二羟基丙酮的效率是游离酶体系的2.5倍,具有良好的复用性。Lai等人合成了氨基功能化的氧化石墨烯,用于共价固定化乳糖酶,在最佳温度下固定化效率达到61%,酶活回收为95%左右,与游离酶相比固定化乳糖酶在酸碱性环境、高温下更稳定,且可多次循环利用。Immobilized enzyme technology is widely used in biocatalysis. Wu et al. used diatomaceous earth and macroporous resin HPD-417 as adsorption carriers and combined them with cellulose derivative membrane coating to immobilize laccase. The enzyme activity recovery rate of the prepared diatomaceous earth and HPD-417 immobilized laccase can reach 99.33% and 94.15%, and the thermal stability and pH tolerance are greatly improved, which has great potential in environmental governance. Nuraliyah et al. used macroporous anionic resin MP-64 and chitosan-treated macroporous non-ionic resin XAD-7HP to adsorb lipase, and then cross-linked with glutaraldehyde. The enzyme activity recovery rate and specific enzyme activity of the prepared MP-64 resin immobilized enzyme reached 83.79% and 29.41U/g. After the immobilized enzyme was used four times in a cycle, the biodiesel synthesis rate was 70.61% of the initial yield. Meng-Qiu Xu et al. co-immobilized glycerol dehydrogenase and NADH oxidase into cross-linked enzyme aggregates to construct an NAD + regeneration system. The specific enzyme activity of the cross-linked enzyme aggregate is 950U/g, and its stability to solution pH and temperature is better than that of the free enzyme. After 10 batches of repeated use, the remaining activity is still 63.3%. Its efficiency in catalyzing glycerol to synthesize 1,3-dihydroxyacetone is 2.5 times that of the free enzyme system, and it has good reusability. Lai et al. synthesized amino-functionalized graphene oxide for covalent immobilization of lactase. The immobilization efficiency reached 61% at the optimal temperature, and the enzyme activity recovery was about 95%. Compared with the free enzyme, the immobilized lactase is more stable in acidic and alkaline environments and high temperatures, and can be recycled many times.
由文献可知固定化酶具有众多优势,固定化酶方法众多,但由于每种酶的蛋白质结构不同,适用于该酶的固定化方法也不同。查阅文献发现,目前少有性能理想、工业化潜力强的固定化腈水解酶。因此,将固定化酶技术应用到腈水解酶上并用于加巴喷丁中间体的合成,将具有较大优势。It is known from the literature that immobilized enzymes have many advantages and there are many methods for immobilizing enzymes. However, due to the different protein structures of each enzyme, the immobilization methods suitable for the enzyme are also different. It is found from the literature that there are currently few immobilized nitrilase with ideal performance and strong industrialization potential. Therefore, applying immobilized enzyme technology to nitrilase and using it for the synthesis of gabapentin intermediates will have great advantages.
(三)发明内容(III) Summary of the invention
本发明目的是提供一种高效腈水解酶固定化方法及在制备加巴喷丁中间体1-氰基环己基乙酸中的应用。本发明使用吸附和/或交联技术,实现了腈水解酶固定化酶的高效制备,得到的固定化酶的酶活回收率高,重复使用性好,储存稳定性极佳。将所得固定化酶应用于催化1-氰基环己基乙腈合成1-氰基环己基乙酸,提高了底物浓度、转化率、酶活回收率、反应批次等主要指标。The present invention aims to provide an efficient nitrilase immobilization method and its application in preparing 1-cyanocyclohexyl acetic acid, an intermediate of gabapentin. The present invention uses adsorption and/or cross-linking technology to achieve efficient preparation of nitrilase immobilized enzyme, and the obtained immobilized enzyme has high enzyme activity recovery rate, good reusability and excellent storage stability. The obtained immobilized enzyme is applied to catalyze 1-cyanocyclohexyl acetonitrile to synthesize 1-cyanocyclohexyl acetic acid, thereby improving the main indicators such as substrate concentration, conversion rate, enzyme activity recovery rate, reaction batch and the like.
本发明采用的技术方案是:The technical solution adopted by the present invention is:
本发明提供一种提高酶学性能的高效腈水解酶固定化方法,所述固定化方法是采用吸附法或交联-吸附法,以大孔树脂为载体,以含腈水解酶编码基因的工程菌经发酵培养获得的纯酶液为活性组分,制备获得固定化腈水解酶;所述腈水解酶编码基因的核苷酸序列如SEQ ID NO.1所示,编码腈水解酶的氨基酸序列如SEQ ID NO.2所示。The invention provides a high-efficiency nitrilase immobilization method for improving enzymatic performance. The immobilization method adopts an adsorption method or a cross-linking-adsorption method, uses a macroporous resin as a carrier, and uses a pure enzyme solution obtained by fermentation and culturing an engineered bacterium containing a nitrilase encoding gene as an active component to prepare immobilized nitrilase; the nucleotide sequence of the nitrilase encoding gene is shown in SEQ ID NO.1, and the amino acid sequence encoding the nitrilase is shown in SEQ ID NO.2.
进一步,所述纯酶液按如下方法制备:将含腈水解酶编码基因的重组大肠杆菌接种至含终浓度50μg/mL卡那霉素抗性的LB液体培养基试管中,在37℃、180rpm下培养8~12h,再以体积浓度1%的接种量接种至新鲜的含终浓度50μg/mL卡那霉素抗性的LB液体培养基摇瓶中,置于37℃、150rpm的摇床中培养2~3h至菌体OD600达0.6~0.8,再加入终浓度0.1mM的IPTG,28℃下诱导培养8~12h后,在4℃、8000rpm条件下离心10min,弃去上清液,收集湿菌体;取0.9g湿菌体,悬浮于30mL pH7.0、200mM磷酸钠缓冲液中,在冰浴中,于破碎功率240W、破碎1s停2s的条件下超声破碎30min,破碎液在4℃、12000rpm条件下离心10min,取上清液即为粗酶液;粗酶液采用Ni柱进行蛋白纯化,上样流速1.5mL/min,以含50mM咪唑的pH6-8、200mM磷酸钠缓冲液洗脱杂蛋白至紫外检测信号降低到基线,用含50mM咪唑的pH 6-8、200mM磷酸钠缓冲液平衡Ni柱,洗脱5个柱体积,再用含500mM咪唑的pH 6-8、200mM磷酸钠缓冲液洗脱,根据紫外检测器的信号改变,收集洗脱峰,收集液透析纯化(透析袋截留分子量14kDa,透析液采用50mM、pH7磷酸钠缓冲液),取截流液,得到腈水解酶纯酶液;所述磷酸钠缓冲液优选200mM、pH 8的磷酸钠缓冲液。Furthermore, the pure enzyme solution is prepared as follows: the recombinant Escherichia coli containing the nitrilase encoding gene is inoculated into a test tube of LB liquid culture medium containing a final concentration of 50 μg/mL kanamycin resistance, and cultured at 37°C and 180 rpm for 8 to 12 hours, and then inoculated into a fresh LB liquid culture medium shake flask containing a final concentration of 50 μg/mL kanamycin resistance at an inoculum concentration of 1% by volume, and cultured in a shaker at 37°C and 150 rpm for 2 to 3 hours until the bacterial OD 600 reaches 0.6 to 0.8, and then IPTG with a final concentration of 0.1 mM is added, and after induction culture at 28°C for 8 to 12 hours, the supernatant is discarded and the wet bacterial cells are collected; 0.9 g of the wet bacterial cells are taken and suspended in 30 mL The enzyme was ultrasonically disrupted for 30 min in an ice bath at a power of 240 W and a 1-s break and 2-s rest period in a pH 7.0, 200 mM sodium phosphate buffer. The disrupted solution was centrifuged at 4°C and 12,000 rpm for 10 min, and the supernatant was the crude enzyme solution. The crude enzyme solution was purified using a Ni column at a flow rate of 1.5 mL/min. The impurities were eluted with a pH 6-8, 200 mM sodium phosphate buffer containing 50 mM imidazole until the ultraviolet detection signal decreased to the baseline. The Ni column was equilibrated with a pH 6-8, 200 mM sodium phosphate buffer containing 50 mM imidazole, eluted for 5 column volumes, and then eluted with a pH 6-8, 200 mM sodium phosphate buffer containing 50 mM imidazole. 6-8, eluted with 200mM sodium phosphate buffer, collecting the elution peak according to the signal change of the UV detector, dialysis purification of the collected liquid (dialysis bag molecular weight cutoff 14kDa, dialysate using 50mM, pH7 sodium phosphate buffer), taking the intercepted liquid to obtain a pure nitrilase enzyme solution; the sodium phosphate buffer is preferably 200mM, pH 8 sodium phosphate buffer.
进一步,所述吸附法按如下步骤进行:将大孔树脂浸入纯酶液中,在25~55℃、100~200rpm条件下水浴搅拌吸附固定化1~3h(优选30℃、130rpm),抽滤,滤饼用去离子水清洗3~5次,将其置于滤纸上室温干燥,得到固定化腈水解酶,记为AcN@大孔树脂。所述纯酶液的蛋白浓度为0.5-2mg/mL,优选1mg/mL;所述纯酶液用量以蛋白含量计为5-15mg/g树脂,优选10mg/g树脂。Further, the adsorption method is carried out according to the following steps: immersing the macroporous resin in the pure enzyme solution, adsorbing and immobilizing for 1 to 3 hours (preferably 30°C, 130rpm) in a water bath under the conditions of 25 to 55°C and 100 to 200rpm, filtering, washing the filter cake with deionized water for 3 to 5 times, placing it on filter paper and drying it at room temperature, and obtaining immobilized nitrilase, which is recorded as AcN@macroporous resin. The protein concentration of the pure enzyme solution is 0.5-2mg/mL, preferably 1mg/mL; the amount of the pure enzyme solution is 5-15mg/g resin in terms of protein content, preferably 10mg/g resin.
进一步,所述交联-吸附法按如下步骤进行:大孔树脂加入到含体积浓度0.25~1.00%(优选0.5%,v/v)戊二醛的磷酸钠缓冲液(优选200mM、pH 6~8)中,在25~55℃、100~200rpm摇床交联0.5-3h(优选35℃、130rpm、3h),用去离子水洗涤3~5次直至检测不到戊二醛;再加入纯酶液,在25~55℃、100~200rpm条件下水浴搅拌吸附固定化1~3h(优选35℃、130rpm、2h),抽滤,滤饼用去离子水清洗3~5次,将其置于滤纸上室温干燥,得到固定化腈水解酶,记为AcN-C@大孔树脂。所述含戊二醛的磷酸缓冲液体积用量以大孔树脂质量计为5-15mL/g,优选10mL/g;所述纯酶液用量以蛋白含量计为5-15mg/g树脂,优选10mg/g树脂。Further, the cross-linking-adsorption method is carried out according to the following steps: the macroporous resin is added to a sodium phosphate buffer (preferably 200 mM, pH 6-8) containing glutaraldehyde at a volume concentration of 0.25-1.00% (preferably 0.5%, v/v), cross-linked for 0.5-3h (preferably 35°C, 130 rpm, 3h) on a shaker at 25-55°C and 100-200 rpm, and washed with deionized water for 3-5 times until glutaraldehyde is no longer detected; then the pure enzyme solution is added, and adsorbed and immobilized for 1-3h (preferably 35°C, 130 rpm, 2h) in a water bath under the conditions of 25-55°C and 100-200 rpm, filtered, and the filter cake is washed with deionized water for 3-5 times, and placed on filter paper to dry at room temperature to obtain immobilized nitrilase, which is recorded as AcN-C@macroporous resin. The volume of the phosphate buffer containing glutaraldehyde is 5-15 mL/g, preferably 10 mL/g, based on the mass of the macroporous resin; the amount of the pure enzyme solution is 5-15 mg/g resin, preferably 10 mg/g resin, based on the protein content.
进一步,所述大孔树脂型号为下列之一:AB-8、201*7、D001、D113、D115、D201、D730、D750、HPD750,优选为D730和D750,更优选D730。Furthermore, the macroporous resin model is one of the following: AB-8, 201*7, D001, D113, D115, D201, D730, D750, HPD750, preferably D730 and D750, more preferably D730.
进一步,所述大孔树脂在固定化前先进行活化预处理:将大孔树脂加入体积浓度75~95%乙醇水溶液中,置于25℃浸泡12h,再用去离子水洗涤3~5次至无乙醇气味,抽滤,滤饼于65℃烘箱中烘干至恒重,得到预处理后的大孔树脂;所述大孔树脂质量用量以乙醇水溶液体积计为15~100g/L,优选100g/L。Furthermore, the macroporous resin is pre-activated before immobilization: the macroporous resin is added to an ethanol aqueous solution with a volume concentration of 75-95%, immersed at 25°C for 12 hours, washed with deionized water for 3-5 times until there is no ethanol smell, filtered, and the filter cake is dried in an oven at 65°C to constant weight to obtain the pre-treated macroporous resin; the mass dosage of the macroporous resin is 15-100 g/L based on the volume of the ethanol aqueous solution, preferably 100 g/L.
本发明还提供一种所述方法制备的固定化腈水解酶在制备1-氰基环己基乙酸中的应用。The present invention also provides an application of the immobilized nitrilase prepared by the method in preparing 1-cyanocyclohexylacetic acid.
所述应用的方法为:以固定化腈水解酶为催化剂,以1-氰基环己基乙腈为底物,以pH 7.0、200mM磷酸钠缓冲液为反应介质构成水相反应体系,在25~55℃、110~150rpm条件(优选35℃、130rpm)下反应1~3h,反应完全后,将混合液抽滤,回收固定化酶,滤液分离纯化,得到所述产物1-氰基环己基乙酸。The application method comprises the following steps: using immobilized nitrilase as a catalyst, 1-cyanocyclohexylacetonitrile as a substrate, and pH 7.0, 200 mM sodium phosphate buffer as a reaction medium to form an aqueous phase reaction system, reacting for 1 to 3 hours at 25 to 55° C. and 110 to 150 rpm (preferably 35° C. and 130 rpm), and after the reaction is complete, filtering the mixed solution, recovering the immobilized enzyme, and separating and purifying the filtrate to obtain the product 1-cyanocyclohexylacetic acid.
进一步,固定化腈水解酶蛋白载量为0.50~10mg/g(优选10mg/g),固定化腈水解酶用量以水相反应体系体积计为20~200g/L(优选100g/L);底物加入浓度以水相反应体系体积计为0.2-1M。Furthermore, the immobilized nitrilase protein loading is 0.50-10 mg/g (preferably 10 mg/g), the immobilized nitrilase dosage is 20-200 g/L (preferably 100 g/L) based on the volume of the aqueous phase reaction system; and the substrate addition concentration is 0.2-1 M based on the volume of the aqueous phase reaction system.
所述的滤液分离纯化方法可为絮凝-萃取法:向反应液中,加入终浓度10g/L的聚氯化铝并在常温下搅拌4h;再加入终浓度10g/L的硅藻土,常温搅拌2h;抽滤,去掉固体,收集滤液;再使用浓盐酸将滤液pH调至1-3(优选2);加入等体积的二氯甲烷,350rpm条件下搅拌15min,于分液漏斗静置10min,收集水相,重复萃取3次;取有机相,25℃旋蒸至固体恒重,获得1-氰基环己基乙酸。The filtrate separation and purification method can be a flocculation-extraction method: add polyaluminium chloride with a final concentration of 10 g/L to the reaction solution and stir at room temperature for 4 hours; then add diatomaceous earth with a final concentration of 10 g/L and stir at room temperature for 2 hours; filter to remove solids and collect the filtrate; then use concentrated hydrochloric acid to adjust the pH of the filtrate to 1-3 (preferably 2); add an equal volume of dichloromethane, stir at 350 rpm for 15 minutes, let stand in a separatory funnel for 10 minutes, collect the aqueous phase, and repeat the extraction 3 times; take the organic phase, and rotary evaporate at 25°C until the solid is constant weight to obtain 1-cyanocyclohexylacetic acid.
与现有方法相比,本发明有益效果主要体现在:Compared with the existing methods, the beneficial effects of the present invention are mainly reflected in:
(1)本发明提供的高效腈水解固定化方法,操作条件简单,物料成本低廉,便于进行放大;制备的固定化酶催化效率高,可多批次重复使用,储存时间长,易于分离。(1) The high-efficiency nitrile hydrolysis immobilization method provided by the present invention has simple operating conditions, low material cost, and is easy to scale up; the prepared immobilized enzyme has high catalytic efficiency, can be reused in multiple batches, has a long storage time, and is easy to separate.
(2)本发明方法制备的固定化腈水解酶的总酶活回收率>77%,最高可以达到100%。固定化腈水解酶的储存稳定性非常好,AcN@D730和AcN-C@D730阴干后在4℃冰箱放置6个月,剩余酶活分别达到66.67%和80.23%。(2) The total enzyme activity recovery rate of the immobilized nitrilase prepared by the method of the present invention is >77%, and can reach up to 100%. The storage stability of the immobilized nitrilase is very good. After AcN@D730 and AcN-C@D730 were dried in the shade and placed in a refrigerator at 4°C for 6 months, the remaining enzyme activities reached 66.67% and 80.23%, respectively.
(2)以固定化腈水解酶作为生物催化剂进行1-氰基环己基乙酸(1-CA)的制备,生物催化剂浓度100g/L,底物浓度200mM,反应2h,底物完全转化,产物得率在98%以上。将固定化腈水解酶回收利用,复用性和稳定性非常好,在30批次反应后转入4℃存放30天,取出后仍可在2小时内完全转化200mM底物,各批次底物转化率均大于99%。(2) 1-Cyanocyclohexylacetic acid (1-CA) was prepared using immobilized nitrilase as a biocatalyst. The biocatalyst concentration was 100 g/L, the substrate concentration was 200 mM, the reaction time was 2 h, the substrate was completely converted, and the product yield was above 98%. The immobilized nitrilase was recycled and had very good reusability and stability. After 30 batches of reactions, it was transferred to 4°C for storage for 30 days. After being taken out, it could still completely convert 200 mM substrate within 2 hours. The substrate conversion rate of each batch was greater than 99%.
(3)本发明方法制备的固定化腈水解酶在制备1-氰基环己基乙酸的反应过程中所需催化剂量少,催化剂复用性和稳定性好,产品产率与纯度高,产物纯化工艺简单,在加巴喷丁药物中间体的工业化生产中具有极高应用价值。本发明开发了新型生物催化制备加巴喷丁关键中间体技术,可简化工艺步骤,减少三废排放。(3) The immobilized nitrilase prepared by the method of the present invention requires a small amount of catalyst in the reaction process of preparing 1-cyanocyclohexylacetic acid, has good catalyst reusability and stability, high product yield and purity, and a simple product purification process, and has extremely high application value in the industrial production of gabapentin drug intermediates. The present invention develops a new biocatalytic technology for preparing key gabapentin intermediates, which can simplify the process steps and reduce the discharge of three wastes.
(四)附图说明(IV) Description of the drawings
图1为以1-氰基环己基乙腈(1-CN)为底物的化学-酶法合成加巴喷丁的路线示意图。FIG1 is a schematic diagram of the chemical-enzymatic synthesis of gabapentin using 1-cyanocyclohexylacetonitrile (1-CN) as a substrate.
图2为表达质粒pET28b-AcN-T图谱。Figure 2 is a map of the expression plasmid pET28b-AcN-T.
(五)具体实施方式(V) Specific implementation methods
下面结合具体实施例对本发明进行进一步描述,但本发明的保护范围并不仅限于此:The present invention is further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited thereto:
本发明实施例大孔树脂各个型号AB-8、201*7、D001、D113、D115、D201、D730、D750、HPD750均购自浙江争光实业股份有限公司。The macroporous resins of various types AB-8, 201*7, D001, D113, D115, D201, D730, D750, and HPD750 in the embodiments of the present invention are all purchased from Zhejiang Zhengguang Industrial Co., Ltd.
200mM、pH 7.0的磷酸钠缓冲液配制:称取二水合磷酸二氢钠12.17g,十二水合磷酸氢二钠43.7g,加去离子水定容到1000mL,调节pH至7.0。Preparation of 200 mM sodium phosphate buffer, pH 7.0: weigh 12.17 g of sodium dihydrogen phosphate dihydrate and 43.7 g of disodium hydrogen phosphate dodecahydrate, add deionized water to make up to 1000 mL, and adjust the pH to 7.0.
本发明敏捷食酸菌Acidovorax facilis ZJB09122,保藏在中国典型培养物保藏中心,保藏编号为CCTCC No.M209044,已在先前申请的专利CN101629192B中披露。本发明腈水解酶采用重组腈水解酶突变体AcN-T及其编码基因,已在先前申请的专利CN111172140B中披露。The Acidovorax facilis ZJB09122 of the present invention is deposited in the China Center for Type Culture Collection with a deposit number of CCTCC No.M209044, and has been disclosed in the previously applied patent CN101629192B. The nitrilase of the present invention uses a recombinant nitrilase mutant AcN-T and its encoding gene, which has been disclosed in the previously applied patent CN111172140B.
实施例1:腈水解酶基因工程菌的构建及培养Example 1: Construction and cultivation of nitrilase genetically engineered bacteria
(1)腈水解酶基因工程菌的构建:(1) Construction of nitrilase genetically engineered bacteria:
参照专利申请CN111172140B,合成源自敏捷食酸菌(A.facilis)CCTCCNO:M209044腈水解酶的突变体AcN-T的基因序列(核苷酸序列SEQ ID NO.1所示,编码蛋白氨基酸序列为SEQ ID NO.2所示),测序后利用BspHI和BsiWI(GTACC)限制性内切酶(TaKaRa)对扩增片段进行处理,利用T4 DNA连接酶(TaKaRa)将该片段同用相同的限制性内切酶处理的商业化载体pET-28b(Invitrogen)进行连接,构建表达载体pET-28b(+)-AcN-T(Xiong N,etal.Biochem.Eng.J.,2022,184:108475.),质粒图谱见图2。Referring to patent application CN111172140B, the gene sequence of the mutant AcN-T derived from the nitrilase of A. facilis CCTCCNO:M209044 was synthesized (the nucleotide sequence is shown in SEQ ID NO.1, and the amino acid sequence of the encoded protein is shown in SEQ ID NO.2). After sequencing, the amplified fragment was treated with BspHI and BsiWI (GTACC) restriction endonucleases (TaKaRa), and the fragment was connected to the commercial vector pET-28b (Invitrogen) treated with the same restriction endonuclease using T4 DNA ligase (TaKaRa) to construct the expression vector pET-28b (+)-AcN-T (Xiong N, et al. Biochem. Eng. J., 2022, 184: 108475.), and the plasmid map is shown in Figure 2.
将构建的表达载体pET-28b(+)-AcN-T转化至大肠杆菌BL21(DE3)(Invitrogen)中(42℃,90s),涂布于含有50μg/mL卡那霉素抗性的LB平板,37℃下培养8-12h,随机挑取克隆抽提质粒进行测序鉴定,筛选获得含有表达质粒pET-28b(+)-AcN-T的重组大肠杆菌BL21(DE3)/pET-28b(+)-AcN-T。The constructed expression vector pET-28b(+)-AcN-T was transformed into Escherichia coli BL21(DE3) (Invitrogen) (42°C, 90s), spread on an LB plate containing 50 μg/mL kanamycin resistance, and cultured at 37°C for 8-12h. Clones were randomly picked and plasmids were extracted for sequencing and identification. Recombinant Escherichia coli BL21(DE3)/pET-28b(+)-AcN-T containing the expression plasmid pET-28b(+)-AcN-T was screened and obtained.
(2)工程菌的培养:(2) Cultivation of engineered bacteria:
将步骤(1)构建的重组大肠杆菌接种至含有终浓度50μg/mL卡那霉素抗性的LB液体培养基试管中,在37℃、180rpm下培养8~12h,再以体积浓度1%的接种量接种至新鲜的含有终浓度50μg/mL卡那霉素抗性的LB液体培养基摇瓶中,置于37℃、150rpm的摇床中培养2~3h后至菌体OD600达0.6~0.8,再加入终浓度0.1mM的IPTG,28℃下诱导培养8~12h后,在4℃、8000rpm条件下离心10min,弃去上清液,收集沉淀,即获得重组大肠杆菌的湿菌体。The recombinant Escherichia coli constructed in step (1) was inoculated into a test tube containing LB liquid culture medium with a final concentration of 50 μg/mL kanamycin resistance, and cultured at 37°C and 180 rpm for 8 to 12 h. Then, the inoculum was inoculated into a fresh shake flask containing LB liquid culture medium with a final concentration of 50 μg/mL kanamycin resistance at a volume concentration of 1%, and cultured in a shaker at 37°C and 150 rpm for 2 to 3 h until the bacterial OD600 reached 0.6 to 0.8. IPTG with a final concentration of 0.1 mM was then added, and after induction culture at 28°C for 8 to 12 h, the culture was centrifuged at 4°C and 8000 rpm for 10 min, the supernatant was discarded, and the precipitate was collected to obtain wet bacterial cells of the recombinant Escherichia coli.
实施例2:腈水解酶游离酶的提取和纯化Example 2: Extraction and purification of free nitrilase enzyme
(1)粗酶液:称取0.9g实施例1制备的湿菌体,悬浮在30mL的200mM、pH7.0磷酸钠缓冲液中,置于冰中保持低温环境,放置在超声细胞破碎仪中,调整破碎频率破1s停2s,破碎功率为240W,破碎30min左右观察到溶液相对澄清即可。之后将破碎后的溶液放置在离心管中,于12000rpm,4℃离心10min,收集上清液即为腈水解酶粗酶液。(1) Crude enzyme solution: Weigh 0.9 g of the wet cells prepared in Example 1, suspend in 30 mL of 200 mM, pH 7.0 sodium phosphate buffer, place in ice to maintain a low temperature environment, place in an ultrasonic cell disruptor, adjust the disruption frequency to break for 1 second and stop for 2 seconds, and the disruption power is 240 W. Disrupt for about 30 minutes until the solution is relatively clear. Then place the disrupted solution in a centrifuge tube, centrifuge at 12000 rpm, 4°C for 10 minutes, and collect the supernatant as the crude nitrilase enzyme solution.
(2)Ni柱的预处理:使用相当于5倍柱体积的去离子水洗涤Ni柱(如ThermoScientific HisPur Ni-NTA Spin Columns)除去保柱所用的乙醇,再用5倍柱体积的pH8.0无咪唑磷酸钠缓冲液(含50mM磷酸二氢钠和300mM氯化钠)冲洗Ni柱,最后用5倍柱体积含50mM咪唑的pH 8.0、200mM磷酸钠缓冲液冲洗至基线平稳。(2) Pretreatment of Ni column: Use 5 column volumes of deionized water to wash the Ni column (such as ThermoScientific HisPur Ni-NTA Spin Columns) to remove the ethanol used to preserve the column, then rinse the Ni column with 5 column volumes of pH 8.0 imidazole-free sodium phosphate buffer (containing 50 mM sodium dihydrogen phosphate and 300 mM sodium chloride), and finally rinse with 5 column volumes of pH 8.0, 200 mM sodium phosphate buffer containing 50 mM imidazole until the baseline is stable.
(3)粗蛋白上样:将粗酶液用0.45μm无菌微孔滤膜过滤处理后以1.5mL/min流速上样,用含50mM咪唑的pH 8.0、200mM磷酸钠缓冲液冲洗管路和Ni柱,将杂蛋白洗脱,直至紫外检测信号降低到基线并保持稳定即为Ni柱冲洗平衡。(3) Loading crude protein: The crude enzyme solution was filtered through a 0.45 μm sterile microporous filter membrane and loaded at a flow rate of 1.5 mL/min. The pipeline and Ni column were flushed with a pH 8.0, 200 mM sodium phosphate buffer containing 50 mM imidazole to elute the impurities until the UV detection signal dropped to the baseline and remained stable, which was the Ni column flushing equilibrium.
(4)洗脱和收样:将步骤(3)平衡后的结合腈水解酶蛋白的Ni柱先用含500mM咪唑的pH 8.0、200mM磷酸钠缓冲液冲洗,当紫外检测器的信号上升时,收集洗脱峰直至紫外检测器信号下降至基线时停止收集,得到纯酶液,用于透析后使用。(4) Elution and sample collection: The Ni column bound to the nitrilase protein after equilibration in step (3) is first rinsed with a pH 8.0, 200 mM sodium phosphate buffer containing 500 mM imidazole. When the signal of the UV detector rises, the elution peak is collected until the UV detector signal drops to the baseline. Collection is stopped to obtain a pure enzyme solution for use after dialysis.
(5)色谱柱再生与保存:将腈水解酶洗脱下来之后,先用5倍柱体积的50mM咪唑pH8.0、200mM磷酸钠缓冲液冲洗镍柱,再用5倍体积超纯水清洗Ni柱,最后用20%的乙醇冲洗,直至显示器显示电导率为0mS左右即可,卸下Ni柱于4℃冰箱保存。(5) Column regeneration and storage: After eluting the nitrilase, rinse the nickel column with 5 times the column volume of 50 mM imidazole pH 8.0, 200 mM sodium phosphate buffer, then wash the Ni column with 5 times the volume of ultrapure water, and finally rinse with 20% ethanol until the display shows that the conductivity is about 0 mS. Remove the Ni column and store it in a refrigerator at 4°C.
(6)透析纯化:首先对透析袋(截留分子量14kDa)进行沸水浴10~15min的前处理,然后取出冷却,将纯酶液利用移液枪转移至透析袋内,将透析袋放置在50mM、pH7磷酸钠缓冲液中,对含高咪唑的腈水解酶液进行透析,透析袋两端用防漏夹夹紧,置于4℃冰箱内透析12h,取截流液即为腈水解酶AcN-T纯酶液。(6) Dialysis purification: First, pre-treat the dialysis bag (molecular weight cutoff 14 kDa) in a boiling water bath for 10 to 15 min, then take it out and cool it. Transfer the pure enzyme solution to the dialysis bag using a pipette. Place the dialysis bag in 50 mM, pH 7 sodium phosphate buffer and dialyze the nitrilase solution containing high imidazole. Clamp both ends of the dialysis bag with leak-proof clamps and place it in a 4°C refrigerator for 12 h. The intercepted liquid is the pure enzyme solution of nitrilase AcN-T.
(7)凝胶电泳及蛋白浓度检测:采用SDS-PAGE电泳对纯化后的腈水解酶蛋白纯度进行检测。(7) Gel electrophoresis and protein concentration detection: SDS-PAGE electrophoresis was used to detect the purity of the purified nitrilase protein.
采用BCA蛋白试剂盒,使用酶标仪测定牛血清白蛋白标准品在562nm处的吸光值(吸光值与标准蛋白含量成正比),最后绘制即时的标准曲线。The BCA protein kit was used to measure the absorbance of the bovine serum albumin standard at 562 nm using an enzyme-labeled instrument (the absorbance is proportional to the standard protein content), and finally a real-time standard curve was drawn.
再采用BCA蛋白试剂盒测试步骤(6)纯酶液562nm处的吸光值,根据标准曲线计算得到腈水解酶纯酶液中的蛋白含量。用200mM、pH 7磷酸钠缓冲液调整蛋白浓度至1mg/mL,得到腈水解酶AcN-T纯酶液,用于后续实验。The absorbance of the pure enzyme solution in step (6) at 562 nm was tested using a BCA protein kit, and the protein content in the pure nitrilase solution was calculated based on the standard curve. The protein concentration was adjusted to 1 mg/mL using 200 mM, pH 7 sodium phosphate buffer to obtain the pure nitrilase AcN-T enzyme solution for subsequent experiments.
实施例3:1-氰基环己基乙酸(1-CA)的液相检测方法及腈水解酶的活力测定Example 3: Liquid Phase Detection Method of 1-Cyanocyclohexylacetic Acid (1-CA) and Determination of Nitrilase Activity
采用高效液相色谱法对1-氰基环己基乙酸(1-CA)进行分析,液相色谱仪器:岛津公司,仪器型号SPD-16型,色谱柱类型为XBridgeBEH C18 Column(5μm,4.6mm×250mm,Waters);流动相为76%缓冲液(0.58g/L NH4H2PO4和1.83g/LNaClO4,pH 1.8)和24%乙腈;检测波长为215nm;流速为1.0mL/min;柱温:40℃;进样量:10μL;分析时间为20min。1-Cyanocyclohexylacetic acid (1-CA) was analyzed by high performance liquid chromatography. The liquid chromatography instrument was Shimadzu Corporation, the instrument model was SPD-16, and the chromatographic column type was XBridgeBEH C18 Column ( 5μm, 4.6mm×250mm, Waters); mobile phase was 76% buffer (0.58g/L NH 4 H 2 PO 4 and 1.83g/L NaClO 4 , pH 1.8) and 24% acetonitrile; detection wavelength was 215nm; flow rate was 1.0mL/min; column temperature: 40℃; injection volume: 10μL; analysis time was 20min.
游离酶酶活测定体系:取1mL(蛋白浓度1mg/mL)实施例2方法制备的腈水解酶AcN-T纯酶液在35℃,700r/min水浴条件下保温10min,加入0.03g底物1-氰基环己基乙腈(1-CN),在35℃,700r/min水浴条件下反应10min;加入微量6M盐酸混匀终止反应,在12000rpm条件下离心1min后,取上清100μL,加入900μL去离子水稀释10倍,过0.22μm有机膜后采用液相色谱检测产物浓度,计算酶活,作为游离酶对照。Free enzyme activity assay system: 1 mL (protein concentration 1 mg/mL) of pure enzyme solution of nitrilase AcN-T prepared by the method of Example 2 was taken and kept warm for 10 min at 35° C. and 700 r/min in a water bath, 0.03 g of substrate 1-cyanocyclohexylacetonitrile (1-CN) was added, and the mixture was reacted for 10 min at 35° C. and 700 r/min in a water bath; a trace amount of 6 M hydrochloric acid was added to mix and terminate the reaction, and after centrifugation at 12000 rpm for 1 min, 100 μL of the supernatant was taken and diluted 10 times with 900 μL of deionized water, and the product concentration was detected by liquid chromatography after passing through a 0.22 μm organic membrane, and the enzyme activity was calculated as a free enzyme control.
树脂固定化酶酶活测定体系:称取1g(蛋白载量10mg/g)固定化腈水解酶,加入10mL 200mM、pH 7磷酸钠缓冲液,在35℃,700r/min水浴条件下保温10min,加入0.3g底物1-氰基环己基乙腈(1-CN),在35℃,700r/min水浴条件下反应10min;加入微量6M盐酸混匀终止反应,在12000rpm条件下离心1min后,取上清100μL,加入900μL去离子水稀释10倍,过0.22μm有机膜后采用液相色谱检测产物浓度,计算酶活。Resin-immobilized enzyme activity assay system: weigh 1 g (protein loading 10 mg/g) of immobilized nitrilase, add 10 mL of 200 mM, pH 7 sodium phosphate buffer, keep warm at 35°C, 700 r/min in a water bath for 10 min, add 0.3 g of substrate 1-cyanocyclohexylacetonitrile (1-CN), react at 35°C, 700 r/min in a water bath for 10 min; add a trace amount of 6 M hydrochloric acid to mix and terminate the reaction, centrifuge at 12000 rpm for 1 min, take 100 μL of the supernatant, add 900 μL of deionized water to dilute 10 times, pass through a 0.22 μm organic membrane, detect the product concentration by liquid chromatography, and calculate the enzyme activity.
酶活单位(U)定义为:在35℃、700r/min条件下,以1-氰基环己基乙腈(1-CN)为底物催化反应10min,每min内催化生成1μmol产物1-氰基环己基乙酸(1-CA)所需的酶量定义为一个酶活力单位(U)。The enzyme activity unit (U) is defined as: at 35°C and 700 r/min, the amount of enzyme required to catalyze the reaction of 1-cyanocyclohexylacetonitrile (1-CN) as a substrate for 10 min, and the amount of enzyme required to catalyze the production of 1 μmol of the product 1-cyanocyclohexylacetic acid (1-CA) per minute is defined as one enzyme activity unit (U).
实施例4:固定化载体树脂材料的筛选Example 4: Screening of immobilized carrier resin materials
分别准确称取1g(干重)AB-8、201*7、D001、D113、D115、D201、D730、D750、HPD750树脂,加入到含有以蛋白含量计1mg/mL实施例2方法制备的腈水解酶AcN-T纯酶液的10mL的200mM,pH 7.0磷酸钠缓冲液中,水浴摇床35℃,130rpm吸附5h结束,抽滤,上清液采用实施例2方法检测蛋白含量,计算蛋白吸附量和蛋白吸附率,并且观察过程中的吸附状态,所得滤饼则直接用200mM、pH 7.0磷酸钠缓冲溶液浸洗3-5次,抽滤除去多余水分后,获得吸附腈水解酶的树脂。不同大孔树脂吸附量见表1所示,优选载体树脂为D730和D750。1g (dry weight) of AB-8, 201*7, D001, D113, D115, D201, D730, D750, and HPD750 resins were accurately weighed respectively, and added to 10mL of 200mM, pH 7.0 sodium phosphate buffer containing 1mg/mL pure enzyme solution of nitrilase AcN-T prepared by the method of Example 2 in terms of protein content, and adsorbed for 5h at 130rpm in a water bath shaker at 35°C, and then filtered by suction. The supernatant was tested for protein content by the method of Example 2, and the protein adsorption amount and protein adsorption rate were calculated, and the adsorption state during the observation process was observed. The obtained filter cake was directly washed with 200mM, pH 7.0 sodium phosphate buffer solution for 3-5 times, and after removing excess water by suction filtration, a resin adsorbing nitrilase was obtained. The adsorption amounts of different macroporous resins are shown in Table 1, and the preferred carrier resins are D730 and D750.
表1:不同大孔树脂吸附量比较Table 1: Comparison of adsorption capacity of different macroporous resins
实施例5:两种方法制备固定化腈水解酶Example 5: Two methods for preparing immobilized nitrilase
1、吸附法制备固定化腈水解酶:1. Preparation of immobilized nitrilase by adsorption method:
(1)树脂预处理:(1) Resin pretreatment:
称取1g大孔树脂D730加入10mL体积浓度75%乙醇水溶液中,置于25℃浸泡12h,再用去离子水洗涤3~5次至无乙醇气味,过滤抽干,最后置于65℃烘箱中烘干12h至恒重,得到预处理后的大孔树脂D730;同样方法制备预处理后的大孔树脂D750。Weigh 1 g of macroporous resin D730 and add it into 10 mL of 75% ethanol aqueous solution, soak it at 25°C for 12 h, wash it with deionized water for 3 to 5 times until there is no ethanol smell, filter and dry it, and finally dry it in a 65°C oven for 12 h to constant weight to obtain the pretreated macroporous resin D730; prepare the pretreated macroporous resin D750 by the same method.
(2)固定化:(2) Immobilization:
称取1g步骤(1)预处理后的大孔树脂加入到10mL含1mg/mL(蛋白浓度)实施例2方法制备的腈水解酶AcN-T纯酶液的200mM,pH 7.0磷酸钠缓冲液中,水浴摇床35℃,130rpm吸附2h,采用实施例2方法测定蛋白吸附率。将吸附后的大孔树脂用去离子水清洗3~5次,置于滤纸上室温干燥,得到吸附法的固定化腈水解酶,记为AcN@D730、AcN@D750,之后放在4℃冰箱保存备用。1 g of the macroporous resin pretreated in step (1) was weighed and added to 10 mL of 200 mM, pH 7.0 sodium phosphate buffer containing 1 mg/mL (protein concentration) of pure nitrilase AcN-T prepared by the method of Example 2, and adsorbed for 2 h in a water bath shaker at 35° C., 130 rpm, and the protein adsorption rate was determined by the method of Example 2. The adsorbed macroporous resin was washed with deionized water for 3 to 5 times, placed on filter paper and dried at room temperature to obtain immobilized nitrilase by adsorption, which was recorded as AcN@D730 and AcN@D750, and then stored in a refrigerator at 4° C. for future use.
2、交联-吸附法制备固定化腈水解酶:2. Preparation of immobilized nitrilase by cross-linking-adsorption method:
(1)树脂预处理:(1) Resin pretreatment:
称取1g大孔树脂D730加入10mL体积浓度75%乙醇水溶液中,置于25℃浸泡12h,再用去离子水洗涤3~5次至无乙醇气味,过滤抽干,最后置于65℃烘箱中烘干12h至恒重,得到预处理后的大孔树脂D730;同样方法制备预处理后的大孔树脂D750。Weigh 1 g of macroporous resin D730 and add it into 10 mL of 75% ethanol aqueous solution, soak it at 25°C for 12 h, wash it with deionized water for 3 to 5 times until there is no ethanol smell, filter and dry it, and finally dry it in a 65°C oven for 12 h to constant weight to obtain the pretreated macroporous resin D730; prepare the pretreated macroporous resin D750 by the same method.
(2)功能化树脂的制备:(2) Preparation of functionalized resin:
将1g步骤(1)预处理后的大孔树脂D730加入10mL含0.5%(v/v)戊二醛的0.2M pH7.0的磷酸钠缓冲液,水浴摇床35℃,130rpm条件下进行交联反应3h,将功能化后的树脂用去离子水清洗3~5次直至检测不到戊二醛气味,得到功能化大孔树脂D730。同样方法制备功能化大孔树脂D750。1 g of the macroporous resin D730 pretreated in step (1) was added to 10 mL of 0.2 M sodium phosphate buffer with pH 7.0 containing 0.5% (v/v) glutaraldehyde, and the cross-linking reaction was carried out for 3 h in a water bath shaker at 35° C. and 130 rpm. The functionalized resin was washed with deionized water for 3 to 5 times until the glutaraldehyde smell was no longer detected, thereby obtaining the functionalized macroporous resin D730. The functionalized macroporous resin D750 was prepared in the same manner.
(3)固定化:(3) Immobilization:
将1g步骤(2)制备的功能化大孔树脂加入到10mL含有实施例2方法制备的以蛋白含量计1mg/mL腈水解酶AcN-T纯酶液的200mM,pH 7.0磷酸缓冲液中,水浴摇床35℃,130rpm吸附2h,固定化结束,采用实施例2方法测定蛋白吸附量。将交联吸附后的大孔树脂用去离子水清洗3~5次,置于滤纸上室温干燥,得到交联-吸附法的固定化腈水解酶,记为AcN-C@D730、AcN-C@D750,之后放在4℃冰箱保存备用。1 g of the functionalized macroporous resin prepared in step (2) was added to 10 mL of 200 mM, pH 7.0 phosphate buffer containing 1 mg/mL pure enzyme solution of nitrilase AcN-T prepared by the method of Example 2, and adsorbed for 2 h in a water bath shaker at 35°C and 130 rpm. After immobilization, the protein adsorption amount was determined by the method of Example 2. The cross-linked adsorbed macroporous resin was washed with deionized water for 3 to 5 times, placed on filter paper and dried at room temperature to obtain immobilized nitrilase by cross-linking-adsorption method, which was recorded as AcN-C@D730 and AcN-C@D750, and then stored in a refrigerator at 4°C for future use.
实施例6:固定化腈水解酶的制备条件Example 6: Preparation conditions of immobilized nitrilase
1、吸附法固定腈水解酶的条件筛选1. Screening of conditions for immobilization of nitrilase by adsorption
(1)吸附率:(1) Adsorption rate:
确定使用树脂D730、D750为固定化酶载体后,在10mL pH 7.0、200mM的磷酸钠(Na2HPO4-NaH2PO4)缓冲液中,分别加入1g(干重)实施例5方法预处理后的树脂D730、D750,再分别加入以蛋白含量计终浓度0.5mg/mL,1.0mg/mL,2.0mg/mL的实施例2方法制备的腈水解酶AcN-T纯酶液,水浴摇床35℃,130rpm吸附5h,采用实施例4方法检测吸附率,结果见表2。After determining to use resin D730 and D750 as immobilized enzyme carriers, 1 g (dry weight) of resin D730 and D750 pretreated by the method of Example 5 were added to 10 mL of pH 7.0, 200 mM sodium phosphate ( Na2HPO4 - NaH2PO4 ) buffer, and then pure enzyme solution of nitrilase AcN-T prepared by the method of Example 2 was added at final concentrations of 0.5 mg/mL, 1.0 mg/mL, and 2.0 mg/mL in terms of protein content, respectively. The mixture was adsorbed on a shaking water bath at 35°C and 130 rpm for 5 h. The adsorption rate was detected by the method of Example 4. The results are shown in Table 2.
吸附结果如下:当酶投量较少时,两种树脂的吸附量均未达到饱和,表现出了较好的吸附效果,蛋白吸附效率可以达到95%左右;而投入酶量较多时,树脂表面或孔隙中的吸附已经达到饱和,腈水解酶的固定化效率较低。The adsorption results are as follows: when the amount of enzyme input is small, the adsorption capacity of both resins has not reached saturation, showing a good adsorption effect, and the protein adsorption efficiency can reach about 95%; when the amount of enzyme input is large, the adsorption on the resin surface or in the pores has reached saturation, and the immobilization efficiency of nitrilase is low.
(2)比酶活:(2) Specific enzyme activity:
将步骤(1)吸附5h后的反应液过滤,滤饼用去离子水清洗3~5次,将其置于滤纸上室温干燥,取1g代替实施例3树脂固定化酶酶活测定体系中固定化腈水解酶进行酶活测定,结果见表2。The reaction solution after adsorption for 5 hours in step (1) was filtered, and the filter cake was washed with deionized water for 3 to 5 times, placed on filter paper and dried at room temperature. 1 g of the mixture was used to replace the immobilized nitrilase in the resin-immobilized enzyme activity assay system of Example 3 for enzyme activity assay. The results are shown in Table 2.
测得每克D730和D750树脂在投入酶量为1.0mg/mL时达到较为理想的比酶活。It was found that the ideal specific enzyme activity was achieved when the enzyme dosage per gram of D730 and D750 resin was 1.0 mg/mL.
考虑到对酶蛋白的利用率,在酶的固定化效率和固定化酶的比酶活之间进行平衡,优选初始酶浓度为10mg/g树脂。Taking into account the utilization of enzyme protein, a balance is struck between the enzyme immobilization efficiency and the specific enzyme activity of the immobilized enzyme, and the preferred initial enzyme concentration is 10 mg/g resin.
表2:不同腈水解酶浓度对两类载体的吸附率和比酶活的影响Table 2: Effect of different nitrilase concentrations on the adsorption rate and specific enzyme activity of two types of carriers
(3)吸附时间(3) Adsorption time
在确定酶载量之后继续探究了两种树脂的吸附时间曲线,在10mL pH 7.0、200mM的磷酸钠缓冲液(Na2HPO4-NaH2PO4)中,分别加入1g(干重)实施例5方法预处理后的树脂D730、D750,再分别加入实施例2方法制备的腈水解酶AcN-T纯酶液10mL(蛋白终浓度1.0mg/mL),水浴摇床35℃,130rpm吸附1、2、3h,采用实施例4方法检测吸附率,结果见表3。After determining the enzyme loading capacity, the adsorption time curves of the two resins were further explored. In 10 mL of pH 7.0, 200 mM sodium phosphate buffer (Na 2 HPO 4 -NaH 2 PO 4 ), 1 g (dry weight) of resins D730 and D750 pretreated by the method of Example 5 were added respectively, and then 10 mL of pure enzyme solution of nitrilase AcN-T prepared by the method of Example 2 (final protein concentration 1.0 mg/mL) was added respectively. The mixture was adsorbed for 1, 2, and 3 h in a water bath shaker at 35° C. and 130 rpm. The adsorption rate was detected by the method of Example 4. The results are shown in Table 3.
结果如下:在加入酶的终浓度为1.0mg/mL时,吸附初期由于树脂吸附远未达到饱和,吸附效率提升很快,在2~3h后吸附效率达到最高,腈水解酶基本完全被树脂吸附。由此可以确定固定化腈水解酶最佳的吸附时间为2~3h。The results are as follows: When the final concentration of the added enzyme is 1.0 mg/mL, the adsorption efficiency increases rapidly in the early stage of adsorption because the resin adsorption is far from saturation. The adsorption efficiency reaches the highest after 2 to 3 hours, and the nitrilase is basically completely adsorbed by the resin. Therefore, it can be determined that the optimal adsorption time for immobilized nitrilase is 2 to 3 hours.
表3:吸附时间对两类载体蛋白吸附率的影响Table 3: Effect of adsorption time on the adsorption rate of two types of carrier proteins
2、交联-吸附法的条件筛选2. Condition screening of cross-linking-adsorption method
在步骤1的最佳蛋白载量和吸附时间条件下,变换固定化方式,先对树脂进行表面功能化处理,再加入酶分子进行交联。由于树脂孔隙有限,选择了分子短小、结构简单的戊二醛对树脂表面进行功能化。Under the optimal protein loading and adsorption time conditions in step 1, the immobilization method was changed, and the resin surface was first functionalized, and then enzyme molecules were added for cross-linking. Due to the limited pores of the resin, glutaraldehyde with short molecules and simple structure was selected to functionalize the resin surface.
(1)功能化试剂浓度(1) Functionalization reagent concentration
将实施例5步骤2中戊二醛的加入体积浓度(v/v)分别改为0.25%、0.5%、0.75%和1%,其他操作相同,通过加入不同浓度的戊二醛进行3h功能化后再进行酶交联,采用实施例2方法测定交联固定化后的树脂的蛋白交联量,采用实施例3方法测定酶活力。The volume concentration (v/v) of glutaraldehyde added in step 2 of Example 5 was changed to 0.25%, 0.5%, 0.75% and 1%, respectively. The other operations were the same. Functionalization was carried out for 3 hours by adding glutaraldehyde of different concentrations and then enzyme cross-linking was performed. The protein cross-linking amount of the resin after cross-linking and immobilization was determined by the method of Example 2, and the enzyme activity was determined by the method of Example 3.
结果见表4,蛋白质的交联率随着交联剂浓度的增加而略微下降,树脂以四种交联剂浓度处理后,在固定化酶量相同的情况下进行酶活测定,当戊二醛浓度在0.5%时的固定化酶,相比较于其他几种浓度交联剂处理的固定化酶表现出了较高的相对酶活,但过高浓度的戊二醛会降低固定化酶的酶活,因此,以体积浓度0.5%为最终功能化试剂的浓度。The results are shown in Table 4. The cross-linking rate of the protein decreased slightly with the increase of the cross-linker concentration. After the resin was treated with four cross-linker concentrations, the enzyme activity was measured under the same amount of immobilized enzyme. When the glutaraldehyde concentration was 0.5%, the immobilized enzyme showed a higher relative enzyme activity compared with the immobilized enzymes treated with other cross-linker concentrations. However, too high a concentration of glutaraldehyde would reduce the enzyme activity of the immobilized enzyme. Therefore, the volume concentration of 0.5% was used as the final concentration of the functionalization reagent.
表4:不同交联剂浓度对载体类型交联率和酶活回收率的影响Table 4: Effects of different cross-linking agent concentrations on carrier type cross-linking rate and enzyme activity recovery rate
(2)功能化试剂交联时间(2) Cross-linking time of functionalized reagents
将实施例5步骤2中戊二醛的加入体积浓度(v/v)改为0.5%,交联时间3h分别改为0.5、1.0、1.5、2.0、2.5、3.0h,其他操作相同,采用实施例2方法测定蛋白吸附率,结果见表5,与实施例5步骤1的吸附法固定化相比,由于功能化基团的加入,蛋白质的交联率相比吸附效率提升很大,在1~3h内交联率几乎可以达到100%,优选交联时间为1~3h。The added volume concentration (v/v) of glutaraldehyde in step 2 of Example 5 was changed to 0.5%, and the cross-linking time of 3h was changed to 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0h respectively. The other operations were the same. The protein adsorption rate was determined by the method of Example 2. The results are shown in Table 5. Compared with the immobilization by adsorption method in step 1 of Example 5, due to the addition of functional groups, the cross-linking rate of the protein was greatly improved compared with the adsorption efficiency. The cross-linking rate can almost reach 100% within 1 to 3h. The preferred cross-linking time is 1 to 3h.
表5:不同交联时间对两类载体交联率的影响Table 5: Effect of different cross-linking times on the cross-linking rates of two types of carriers
实施例7:固定化腈水解酶的最适温度及温度稳定性Example 7: Optimal Temperature and Temperature Stability of Immobilized Nitrilase
(1)最适温度(1) Optimum temperature
选取温度范围为25~55℃来考察不同温度对固定化酶的活力影响。The temperature range of 25-55°C was selected to investigate the effect of different temperatures on the activity of the immobilized enzyme.
分别将1g(蛋白载量均为10mg/g)实施例5方法制备的固定化腈水解酶AcN@D730、AcN@D750、AcN-C@D730、AcN-C@D750加入10mL的pH 7.0、200mM磷酸钠缓冲液,分别在不同温度(25、45、55℃)下保温10min后,再采用实施例3方法测试酶活。将某温度下最高的酶活定性为100%,其余的与最高酶活对比,即为相对酶活。1 g (protein loading of 10 mg/g) of immobilized nitrilase AcN@D730, AcN@D750, AcN-C@D730, and AcN-C@D750 prepared by the method of Example 5 were added to 10 mL of pH 7.0, 200 mM sodium phosphate buffer, and incubated at different temperatures (25, 45, and 55° C.) for 10 min, and then the enzyme activity was tested by the method of Example 3. The highest enzyme activity at a certain temperature was qualitatively defined as 100%, and the rest were compared with the highest enzyme activity, which was the relative enzyme activity.
结果如下:吸附法制备的固定化酶AcN@D730、AcN@D750的最适温度可达到60℃,而吸附-交联法制备的固定化酶AcN-C@D730和AcN-C@D750的最适温度可以达到70℃。The results are as follows: the optimum temperature of immobilized enzymes AcN@D730 and AcN@D750 prepared by adsorption method can reach 60℃, while the optimum temperature of immobilized enzymes AcN-C@D730 and AcN-C@D750 prepared by adsorption-crosslinking method can reach 70℃.
(2)热稳定性(2) Thermal stability
首先将1g(蛋白载量均为10mg/g)实施例5步骤2方法制备的固定化腈水解酶AcN@D730、AcN@D750、AcN-C@D730、AcN-C@D750加入10mL的pH 7.0、200mM磷酸钠缓冲液中,分别放置于25℃、45℃、55℃的恒温水浴锅中保存,在不同的时间(1、5、10、15、20、25天)取样,将原有的缓冲液倒去,加入新的缓冲液,采用实施例3方法测定酶活。将初始的酶活定性为100%,其余的与初始酶活进行对比,计算酶活回收率。AcN-C@D730、AcN-C@D750酶活回收率见表6。First, 1g (protein loading is 10mg/g) of immobilized nitrilase AcN@D730, AcN@D750, AcN-C@D730, AcN-C@D750 prepared by the method of step 2 of Example 5 was added to 10mL of pH 7.0, 200mM sodium phosphate buffer, and placed in a constant temperature water bath at 25°C, 45°C, and 55°C, respectively. Samples were taken at different times (1, 5, 10, 15, 20, 25 days), the original buffer was poured out, new buffer was added, and the enzyme activity was determined by the method of Example 3. The initial enzyme activity was qualitatively 100%, and the rest was compared with the initial enzyme activity to calculate the enzyme activity recovery rate. The enzyme activity recovery rates of AcN-C@D730 and AcN-C@D750 are shown in Table 6.
结果:两种固定化方法(吸附法、交联-吸附法)制备的固定化腈水解酶在25℃,pH7.0、200mM磷酸钠缓冲液条件下放置25天后,酶活仍然可以保持90%以上。其中交联固定化酶AcN-C@D730和AcN-C@D750在45℃条件下放置20天后还有60%以上的酶活剩余,体现出了较好的热稳定性。Results: The immobilized nitrilase prepared by the two immobilization methods (adsorption method, cross-linking-adsorption method) can still maintain more than 90% of its activity after being placed at 25°C, pH 7.0, 200mM sodium phosphate buffer for 25 days. Among them, the cross-linked immobilized enzymes AcN-C@D730 and AcN-C@D750 still have more than 60% of their activity remaining after being placed at 45°C for 20 days, reflecting good thermal stability.
表6:腈水解酶固定化酶的最适温度及温度稳定性Table 6: Optimal temperature and temperature stability of nitrilase immobilized enzyme
(3)半衰期(3) Half-life
将实施例2方法制备的腈水解酶AcN-T的纯酶液、实施例5方法制备的固定化腈水解酶AcN-C@D730和AcN-C@D750分别置于55℃恒温水浴中保温,每隔一段时间取样检测酶活力。以未保温时,蛋白的活力为对照,计算各时间下,蛋白的相对残余活力(RA)。以时间(h)为横坐标,相对残余活力的自然对数(ln(RA))为纵坐标,进行线性拟合,得出斜率k。根据一级失活动力学的公式,可以得到酶蛋白的半衰期t1/2。The pure enzyme solution of nitrilase AcN-T prepared by the method of Example 2, and the immobilized nitrilase AcN-C@D730 and AcN-C@D750 prepared by the method of Example 5 were placed in a 55°C constant temperature water bath for insulation, and samples were taken at regular intervals to detect the enzyme activity. The activity of the protein when not incubated was used as a control to calculate the relative residual activity (RA) of the protein at each time. With time (h) as the abscissa and the natural logarithm of the relative residual activity (ln(RA)) as the ordinate, a linear fit was performed to obtain the slope k. According to the formula of the first-order inactivation kinetics, the half-life t 1/2 of the enzyme protein can be obtained.
AcN-C@D730和AcN-C@D750在55℃下的半衰期分别为480h和240h,相比于游离酶AcN-T的20h,半衰期分别延长了24倍和12倍。The half-lives of AcN-C@D730 and AcN-C@D750 at 55°C were 480 h and 240 h, respectively, which were extended by 24 and 12 times compared with 20 h of the free enzyme AcN-T.
实施例8:固定化腈水解酶最适pH及溶液稳定性Example 8: Optimal pH and solution stability of immobilized nitrilase
(1)最适pH(1) Optimum pH
选取pH范围为6.0~8.0的不同缓冲液来考察不同pH对固定化酶的活力影响。使用的缓冲液体系为柠檬酸-柠檬酸钠缓冲液(50mM),pH 3.0~6.5;磷酸缓冲液(PBS,50mM),pH7.0~8.0。其中最高的酶活力作为100%,从而计算相对酶活进行比较。Different buffers with a pH range of 6.0 to 8.0 were selected to investigate the effect of different pH on the activity of the immobilized enzyme. The buffer system used was citric acid-sodium citrate buffer (50mM), pH 3.0 to 6.5; phosphate buffer (PBS, 50mM), pH 7.0 to 8.0. The highest enzyme activity was taken as 100%, and the relative enzyme activity was calculated for comparison.
将1g(蛋白载量均为10mg/g)实施例5方法制备的固定化腈水解酶AcN@D730、AcN@D750、AcN-C@D730、AcN-C@D750,分别置于10mL的pH 6.0,pH 7.0,pH8.0的不同缓冲液中,采用实施例3的方法测试酶活,结果表明pH为6.0时四种固定化酶达到最优相对酶活为100%。1 g (protein loading of 10 mg/g) of immobilized nitrilase AcN@D730, AcN@D750, AcN-C@D730, and AcN-C@D750 prepared by the method of Example 5 were placed in 10 mL of different buffer solutions of pH 6.0, pH 7.0, and pH 8.0, respectively, and the enzyme activity was tested by the method of Example 3. The results showed that the four immobilized enzymes achieved an optimal relative enzyme activity of 100% when the pH was 6.0.
几种固定化酶在弱酸(pH=6)条件下表现出较高的相对酶活,相比之下游离酶在pH 7.5条件下表现出最高酶活。AcN@D750与AcN-C@D750的最适pH范围(相对酶活>80%)较窄,AcN@D730,AcN-C@D730具有更宽的最适pH范围,其中AcN-C@D730的最适pH为5~6。Several immobilized enzymes showed higher relative enzyme activities under weak acid (pH=6), while free enzymes showed the highest enzyme activity under pH 7.5. The optimal pH ranges of AcN@D750 and AcN-C@D750 (relative enzyme activity>80%) were narrower, while AcN@D730 and AcN-C@D730 had wider optimal pH ranges, with the optimal pH of AcN-C@D730 being 5-6.
(2)溶液稳定性(2) Solution stability
将1g(蛋白载量均为10mg/g)实施例5方法制备的固定化腈水解酶AcN-C@D730和AcN-C@D750,分别加入10mL pH 6.0,pH 7.0,pH 8.0的不同缓冲液中,4℃分别放置1、5、10、15、20、25天,采用实施例3方法测试酶活,将刚开始的酶活定性为100%,其余与初始酶活进行对比。结果见表7所示。几种固定化酶在缓冲液中的稳定性如下,AcN-C@D750在pH为6和pH为7条件下表现出较好的稳定性,放置25天还可以保持90%以上的相对酶活。而AcN-C@D730的稳定性稍弱,pH 6条件下放置20天后只能保持60%的酶活。1g (protein loading of 10mg/g) of immobilized nitrilase AcN-C@D730 and AcN-C@D750 prepared by the method of Example 5 were added to 10mL of different buffers of pH 6.0, pH 7.0, and pH 8.0, respectively, and placed at 4°C for 1, 5, 10, 15, 20, and 25 days, and the enzyme activity was tested by the method of Example 3. The initial enzyme activity was qualitatively 100%, and the rest was compared with the initial enzyme activity. The results are shown in Table 7. The stability of several immobilized enzymes in buffer is as follows: AcN-C@D750 shows good stability under pH 6 and pH 7 conditions, and can maintain more than 90% relative enzyme activity after being placed for 25 days. The stability of AcN-C@D730 is slightly weaker, and can only maintain 60% enzyme activity after being placed under pH 6 conditions for 20 days.
表7:固定化腈水解酶的最适pH及溶液稳定性Table 7: Optimal pH and solution stability of immobilized nitrilase
实施例9:固定化腈水解酶的蛋白脱附Example 9: Protein Desorption of Immobilized Nitrilase
将1g(蛋白载量均为10mg/g)实施例5方法制备的固定化腈水解酶AcN@D730、AcN@D750、AcN-C@D730、AcN-C@D750,置于10mL 200mM,pH 7.0磷酸钠缓冲液中,水浴摇床35℃,130rpm摇晃12h,采用实施例2方法测定溶液中的蛋白含量,计算蛋白脱附率,并且观察溶液状态,重复3个平行实验。结果见表8所示,交联固定化酶的稳定性较高,其中固定化腈水解酶AcN-C@D730蛋白脱附率最低为1.7%。1g (protein loading of 10mg/g) of immobilized nitrilase AcN@D730, AcN@D750, AcN-C@D730, AcN-C@D750 prepared by the method of Example 5 was placed in 10mL 200mM, pH 7.0 sodium phosphate buffer, shaken at 130rpm for 12h in a water bath shaker at 35°C, and the protein content in the solution was determined by the method of Example 2, the protein desorption rate was calculated, and the solution state was observed, and three parallel experiments were repeated. The results are shown in Table 8, and the stability of the cross-linked immobilized enzyme is relatively high, wherein the protein desorption rate of the immobilized nitrilase AcN-C@D730 is the lowest at 1.7%.
表8:固定化腈水解酶的蛋白脱附量Table 8: Protein desorption of immobilized nitrilase
实施例10:固定化腈水解酶催化合成1-氰基环己基乙酸(1-CA)的批次反应(1)低底物浓度批次反应Example 10: Batch reaction of immobilized nitrilase-catalyzed synthesis of 1-cyanocyclohexylacetic acid (1-CA) (1) Batch reaction at low substrate concentration
将1g(蛋白载量均为10mg/g)实施例5方法制备的固定化腈水解酶(AcN@D730、AcN@D750、AcN-C@D730、AcN-C@D750)加入10mL、200mM、pH7.0磷酸钠缓冲液中,加入0.2M底物1-氰基环己基乙腈(1-CN),置于35℃、150rpm的水浴摇床中进行反应。1 g (protein loading of 10 mg/g) of immobilized nitrilase (AcN@D730, AcN@D750, AcN-C@D730, AcN-C@D750) prepared by the method of Example 5 was added to 10 mL, 200 mM, pH 7.0 sodium phosphate buffer, 0.2 M substrate 1-cyanocyclohexylacetonitrile (1-CN) was added, and the mixture was placed in a water bath shaker at 35°C and 150 rpm for reaction.
反应批次:将转化率超过90%定性为一个反应批次。Reaction batch: A reaction batch was defined as one with a conversion rate exceeding 90%.
每次反应结束后收集反应液,用去离子水将固定化酶清洗3~5次后,进行下一个批次的催化反应。反应过程中,取样采用实施例3方法检测底物浓度,计算底物转化率,当一个批次反应结束后,检测产物浓度,计算产物产率。结果见表9,交联固定化酶AcN-C@D750和AcN-C@D730以每批次2h,催化30个批次后底物转化率仍然可以达到100%,吸附固定化酶AcN@D750和AcN@D730在催化20个批次(每批次2h)后,催化转化率下降,交联固定化酶复用性更强。After each reaction, the reaction solution was collected, and the immobilized enzyme was washed 3 to 5 times with deionized water before the next batch of catalytic reaction was carried out. During the reaction, the substrate concentration was detected by the method of Example 3, and the substrate conversion rate was calculated. After a batch of reactions was completed, the product concentration was detected and the product yield was calculated. The results are shown in Table 9. The cross-linked immobilized enzymes AcN-C@D750 and AcN-C@D730 were catalyzed for 2h per batch, and the substrate conversion rate could still reach 100% after 30 batches. The adsorbed immobilized enzymes AcN@D750 and AcN@D730 had a catalytic conversion rate of 20 batches (2h per batch), and the cross-linked immobilized enzymes had a stronger reusability.
表9:腈水解酶固定化酶催化的批次反应Table 9: Batch reactions catalyzed by nitrilase immobilized enzymes
(2)高底物浓度批次反应(2) High substrate concentration batch reaction
为了验证固定化酶对高浓度底物的催化效果,将步骤1的底物浓度改为1M,固定化酶用量100g/L(蛋白载量均为10mg/g),其它条件不变,结果见表10。100g/L的AcN@D750和AcN@D730在7h内可以转化98%左右的底物,AcN-C@D750和AcN-C@D730在5h内可以转化96%左右的底物。In order to verify the catalytic effect of immobilized enzyme on high concentration substrate, the substrate concentration in step 1 was changed to 1 M, the amount of immobilized enzyme was 100 g/L (the protein loading was 10 mg/g), and other conditions remained unchanged. The results are shown in Table 10. 100 g/L of AcN@D750 and AcN@D730 can convert about 98% of the substrate within 7 hours, and AcN-C@D750 and AcN-C@D730 can convert about 96% of the substrate within 5 hours.
将步骤1中固定化腈水解酶改为10g/L实施例1方法制备的湿菌体AcN-T,含酶量约为1600mg/L,其他操作相同,作为游离细胞对照。The immobilized nitrilase in step 1 was replaced with 10 g/L wet bacteria AcN-T prepared by the method of Example 1, with an enzyme content of about 1600 mg/L. Other operations were the same as those of the free cell control.
与游离细胞相比,目前实践中使用10g/L的游离细胞作为催化剂,其含酶量约为1600mg/L,而固定化酶的当量酶用量仅为1000mg/L,且可以重复使用数十个批次,固定化极大提高了酶的催化效率和复用性。所得最优交联固定化腈水解酶催化30个批次后底物转化率仍然可以达到100%。Compared with free cells, currently in practice, 10g/L of free cells are used as catalysts, and the enzyme content is about 1600mg/L, while the equivalent enzyme dosage of immobilized enzyme is only 1000mg/L, and it can be reused for dozens of batches. Immobilization greatly improves the catalytic efficiency and reusability of the enzyme. The optimal cross-linked immobilized nitrilase obtained can still achieve a substrate conversion rate of 100% after catalysis of 30 batches.
表10:固定化腈水解酶催化高浓度底物的批次反应Table 10: Batch reactions of high-concentration substrates catalyzed by immobilized nitrilase
实施例11:固定化腈水解酶的储存稳定性Example 11: Storage stability of immobilized nitrilase
树脂固定化腈水解酶的储存稳定性极佳,超过了目前报道的大多数固定化酶制剂。The storage stability of resin-immobilized nitrilase is excellent, exceeding that of most immobilized enzyme preparations reported so far.
将实施例10中经过30个批次反应后回收的AcN-C@D730和AcN-C@D750,转移到4℃冰箱保存30天后取出,仍然可以在两小时内完全转化200mM底物。The AcN-C@D730 and AcN-C@D750 recovered after 30 batches of reactions in Example 10 were transferred to a 4°C refrigerator and stored for 30 days before being taken out. They could still completely convert 200 mM substrate within two hours.
将0.1g(蛋白载量均为10mg/g)实施例5方法制备的AcN-C@D730和AcN-C@D750放置于1mL 200mM pH7.0磷酸钠缓冲液中,固定化酶最终添加量100g/L,在最适温度(70℃)和最适pH 6条件下保存30天,结果见表11,残余酶活可达到90%以上。0.1 g (protein loading of 10 mg/g) of AcN-C@D730 and AcN-C@D750 prepared by the method of Example 5 was placed in 1 mL of 200 mM pH 7.0 sodium phosphate buffer, with a final addition amount of 100 g/L of immobilized enzyme. It was stored at the optimal temperature (70°C) and optimal pH 6 for 30 days. The results are shown in Table 11. The residual enzyme activity can reach more than 90%.
将实施例5方法制备的固定化腈水解酶AcN@D730、AcN@D750、AcN-C@D730、AcN-C@D750阴干,放置于4℃(室温干燥后存放在EP管中)环境下保存6个月后,进行酶活测定。结果见表11,AcN@D730的剩余酶活达到66.67%,而AcN-C@D730的剩余酶活则达到80.23%。在相同条件下,AcN@D750的剩余酶活只达到28.57%,AcN-C@D750只有19.71%左右的剩余酶活。虽然这两种树脂在交联处理后的催化性能以及储存稳定性都较为良好,但是基于D730树脂的固定化酶在储存性能上的表现更胜一筹。The immobilized nitrilase AcN@D730, AcN@D750, AcN-C@D730, and AcN-C@D750 prepared by the method of Example 5 were dried in the shade, placed in an environment of 4°C (stored in an EP tube after drying at room temperature) for 6 months, and then the enzyme activity was determined. The results are shown in Table 11. The residual enzyme activity of AcN@D730 reached 66.67%, while the residual enzyme activity of AcN-C@D730 reached 80.23%. Under the same conditions, the residual enzyme activity of AcN@D750 only reached 28.57%, and AcN-C@D750 had only about 19.71% residual enzyme activity. Although the catalytic performance and storage stability of these two resins after cross-linking treatment are relatively good, the immobilized enzyme based on D730 resin performs better in storage performance.
表11:固定化腈水解酶的储存稳定性Table 11: Storage stability of immobilized nitrilase
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410214810.0A CN118086272A (en) | 2024-02-27 | 2024-02-27 | High-efficiency nitrilase immobilization method and its application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410214810.0A CN118086272A (en) | 2024-02-27 | 2024-02-27 | High-efficiency nitrilase immobilization method and its application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118086272A true CN118086272A (en) | 2024-05-28 |
Family
ID=91158328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410214810.0A Pending CN118086272A (en) | 2024-02-27 | 2024-02-27 | High-efficiency nitrilase immobilization method and its application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118086272A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118956595A (en) * | 2024-10-15 | 2024-11-15 | 安徽瑞邦生物科技有限公司 | A nitrilase immobilization technology production equipment for nicotinic acid production |
-
2024
- 2024-02-27 CN CN202410214810.0A patent/CN118086272A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118956595A (en) * | 2024-10-15 | 2024-11-15 | 安徽瑞邦生物科技有限公司 | A nitrilase immobilization technology production equipment for nicotinic acid production |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11987826B2 (en) | Nitrilase mutant and application thereof in the synthesis of an anti-epileptic drug intermediate | |
CN107177576B (en) | Nitrilase mutants and their applications | |
CN105624128B (en) | Immobilized monoamine oxidase and application thereof in synthesis of chiral azabicyclo compound | |
EP3533862B1 (en) | Methylopila sp. and use thereof in selective resolution and preparation of (s)-alpha-ethyl-2-oxo-1 -pyrrolidine acetate | |
CN118086272A (en) | High-efficiency nitrilase immobilization method and its application | |
CN110129307B (en) | Immobilized ketoreductase mutant and application thereof in preparation of duloxetine chiral alcohol intermediate and analogue thereof | |
CN103290078B (en) | Method for preparing 5-aminovaleric acid by using L-lysine-2-monooxygenase and delta-valeramide hydrolase as catalysts | |
CN105063010A (en) | Multi-enzyme system with immobilized polyethylenimine and metal coordination and method for preparing multi-enzyme system | |
CN104404026B (en) | A kind of polyethyleneimine titanium oxide for embedding amine dehydrogenase and preparation method thereof | |
CN113801239B (en) | Polypeptide tag, highly soluble recombinant nitrilase and application thereof in synthesis of medicinal chemicals | |
CN105219661A (en) | The special strain therefore of synthesis of oligonucleotides semi-lactosi and the method with its synthesis of oligonucleotides semi-lactosi | |
CN118440142A (en) | Connecting peptide, nitrilase fusion protein and application thereof | |
CN106755155A (en) | A kind of method for preparing beta Alanine with double enzyme series connection | |
CN106011191A (en) | Method for producing 5-aminopentanoic acid by whole-cell biocatalysis | |
Chen et al. | Simultaneous purification and immobilization of penicillin G acylase using bifunctional membrane | |
CN109321490B (en) | Enterobacter aerogenes ZJB-17003 and its application | |
CN114262704B (en) | Immobilized carrier, D-acetylleucine deacetylation immobilized enzyme and preparation method | |
CN105838700A (en) | Immobilized halohydrin dehalogenase and application thereof | |
CN116574750B (en) | A nitrile hydratase recombinant plasmid that improves the bioconversion efficiency of nitrile compounds and its construction method and application | |
CN117535281B (en) | Method for orderly immobilizing multiple enzymes by amino microspheres, product and application thereof | |
Antony et al. | Overview of the Enzyme Support System of Immobilization for Enhanced Efficiency and Reuse of Enzymes | |
CN119144672B (en) | Method for synthesizing rasagiline in micro-flow field | |
CN118291412A (en) | Leucine dehydrogenase and application thereof | |
CN116042599A (en) | In-vitro multienzyme system for producing 5-hydroxytryptophan | |
CN117264941A (en) | Immobilized multienzyme system for producing allitol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |